FY2024 EPS Estimates for Moderna Decreased by Analyst

Moderna, Inc. (NASDAQ:MRNA) – Equities researchers at Brookline Capital Management reduced their FY2024 earnings estimates for shares of Moderna in a research note issued on Monday, January 13th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($9.15) per share for the year, down from their previous estimate of ($9.12). The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. Brookline Capital Management also issued estimates for Moderna’s Q4 2024 earnings at ($2.85) EPS, FY2025 earnings at ($8.56) EPS, FY2026 earnings at ($2.00) EPS, FY2027 earnings at $1.30 EPS and FY2028 earnings at $5.31 EPS.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.39) earnings per share.

MRNA has been the subject of a number of other reports. Jefferies Financial Group decreased their price target on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. Hsbc Global Res raised Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, November 8th. Piper Sandler reiterated an “overweight” rating and set a $69.00 target price (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. Finally, Morgan Stanley reduced their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday. Four analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $75.58.

Moderna Stock Performance

Shares of MRNA stock opened at $33.76 on Thursday. Moderna has a 52-week low of $31.94 and a 52-week high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The stock has a market cap of $12.99 billion, a PE ratio of -5.80 and a beta of 1.60. The business has a 50-day simple moving average of $41.11 and a 200-day simple moving average of $67.32.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares of the company’s stock, valued at $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 2,664 shares of company stock valued at $115,210 in the last 90 days. Company insiders own 15.20% of the company’s stock.

Institutional Trading of Moderna

Several institutional investors have recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC acquired a new position in Moderna during the second quarter worth $26,000. MassMutual Private Wealth & Trust FSB lifted its holdings in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after buying an additional 389 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after acquiring an additional 317 shares in the last quarter. Finally, Rakuten Securities Inc. grew its stake in Moderna by 477.3% during the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after purchasing an additional 778 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.